Thiopurines: Factors influencing toxicity and response

Biochemical Pharmacology

Volumn 79, Issue 9, 2010, Pages 1211-1220

  Fotoohi, Alan Kambiz ^a,b   Coulthard, Sally A ^c,d   Albertioni, Freidoun ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

6 Mercaptopurine; 6 Thioguanine; Acute lymphoblastic leukemia; Azathioprine; Hypoxanthine guanine phosphoribosyl transferase; Inosine 5 monophosphate dehydrogenase; Pharmacogenetics; Thiopurine methyltransferase; Transport

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ANTINEOPLASTIC ANTIMETABOLITE; AZATHIOPRINE; DEOXY 6 THIOGUANOSINE 5' TRIPHOSPHATE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 2; GUANINE MONOPHOSPHATE SYNTHETASE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; INORGANIC PYROPHOSPHATASE; INOSINATE DEHYDROGENASE INHIBITOR; INOSINE TRIPHOSPHATE PYROPHOSPHATASE; MERCAPTOPURINE; MERCAPTOPURINE RIBOSIDE; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; ORGANIC ANION TRANSPORTER 3; SYNTHETASE; THIOGUANINE DERIVATIVE; THIOGUANOSINE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; UNCLASSIFIED DRUG;

ACUTE LYMPHOCYTIC LEUKEMIA; ALLELE; ARTICLE; BIOTRANSFORMATION; BLOOD TOXICITY; BONE MARROW TOXICITY; CELL CYCLE ARREST; CELL TRANSPORT; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; DNA SYNTHESIS INHIBITION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENCY; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG TRANSPORT; ENZYME ACTIVITY; FEBRILE NEUTROPENIA; FLU LIKE SYNDROME; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HODGKIN DISEASE; HOMOZYGOSITY; HUMAN; LIVER TOXICITY; METASTASIS; MISMATCH REPAIR; PANCREATITIS; PASSIVE TRANSPORT; PHARMACODYNAMICS; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PURINE METABOLISM;

EID: 77649179763     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.01.006     Document Type: Note

References (100)

1. Elion G.B., Hitchings G.H., and Vanderwerff H. Antagonists of nucleic acid derivatives. VI. Purines. The Journal of Biological Chemistry 192 (1951) 505-518
2. Burchenal J.H., et al. Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukemia and allied diseases. Blood 8 (1953) 965-999
3. Schwartz R., Stack J., and Dameshek W. Effect of 6-mercaptopurine on antibody production. Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 99 (1958) 164-167
4. Elion G.B. The purine path to chemotherapy. Science (New York, N.Y.) 244 (1989) 41-47
5. Tay B.S., Lilley R.M., Murray A.W., and Atkinson M.R. Inhibition of phosphoribosyl pyrophosphate amidotransferase from Ehrlich ascites-tumour cells by thiopurine nucleotides. Biochemical Pharmacology 18 (1969) 936-938
6. Swann P.F., et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science (New York, N.Y.) 273 (1996) 1109-1111
7. Keuzenkamp-Jansen C.W., et al. Detection and identification of 6-methylmercapto-8-hydoxypurine, a major metabolite of 6-mercaptopurine, in plasma during intravenous administration. Clinical Chemistry 42 (1996) 380-386
8. Kitchen B.J., et al. Thioguanine administered as a continuous intravenous infusion to pediatric patients is metabolized to the novel metabolite 8-hydroxy-thioguanine. The Journal of Pharmacology and Experimental Therapeutics 291 (1999) 870-874
9. Pui C.H., and Evans W.E. Treatment of acute lymphoblastic leukemia. The New England Journal of Medicine 354 (2006) 166-178
10. Coulthard S.A., et al. The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs. Molecular Pharmacology 62 (2002) 102-109
11. Hogarth L.A., et al. The effect of thiopurine drugs on DNA methylation in relation to TPMT expression. Biochemical Pharmacology 76 (2008) 1024-1035
12. Elion G.B. Significance of azathioprine metabolites. Proceedings of the Royal Society of Medicine 65 (1972) 257-260
13. Cory J. Purine and pyrimidine nucleotide metabolism (1986), Wiley, New York
14. Pieters R., et al. Hypoxanthine-guanine phosphoribosyl-transferase in childhood leukemia: relation with immunophenotype, in vitro drug resistance and clinical prognosis. International Journal of Cancer 51 (1992) 213-217
15. Lennard L., Hale J.P., and Lilleyman J.S. Red blood cell hypoxanthine phosphoribosyltransferase activity measured using 6-mercaptopurine as a substrate: a population study in children with acute lymphoblastic leukaemia. British Journal of Clinical Pharmacology 36 (1993) 277-284
16. Zimm S., et al. Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered?. The New England Journal of Medicine 308 (1983) 1005-1009
17. Coulthard S., and Hogarth L. The thiopurines: an update. Investigational New Drugs 23 (2005) 523-532
18. Weinshilboum R.M., and Sladek S.L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. American Journal of Human Genetics 32 (1980) 651-662
19. Tai H.L., et al. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. American Journal of Human Genetics 58 (1996) 694-702
20. Salavaggione O.E., Wang L., Wiepert M., Yee V.C., and Weinshilboum R.M. Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics. Pharmacogenet Genomics 15 (2005) 801-815
21. Yates C.R., et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Annals of Internal Medicine 126 (1997) 608-614
22. Sahasranaman S., Howard D., and Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. European Journal of Clinical Pharmacology 64 (2008) 753-767
23. Hon Y.Y., et al. Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Human Molecular Genetics 8 (1999) 371-376
24. McLeod H.L., Lin J.S., Scott E.P., Pui C.H., and Evans W.E. Thiopurine methyltransferase activity in American white subjects and black subjects. Clinical Pharmacology and Therapeutics 55 (1994) 15-20
25. Otterness D., et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clinical Pharmacology and Therapeutics 62 (1997) 60-73
26. Spire-Vayron de la Moureyre C., et al. Detection of known and new mutations in the thiopurine S-methyltransferase gene by single-strand conformation polymorphism analysis. Human Mutation 12 (1998) 177-185
27. Krynetski E.Y., et al. Promoter and intronic sequences of the human thiopurine S-methyltransferase (TPMT) gene isolated from a human PAC1 genomic library. Pharmaceutical Research 14 (1997) 1672-1678
28. Alves S., Amorim A., Ferreira F., and Prata M.J. Influence of the variable number of tandem repeats located in the promoter region of the thiopurine methyltransferase gene on enzymatic activity. Clinical Pharmacology and Therapeutics 70 (2001) 165-174
29. Karran P., and Attard N. Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nature Reviews 8 (2008) 24-36
30. Spire-Vayron de la Moureyre C., et al. Characterization of a variable number tandem repeat region in the thiopurine S-methyltransferase gene promoter. Pharmacogenetics 9 (1999) 189-198
31. Yan L., et al. Thiopurine methyltransferase polymorphic tandem repeat: genotype-phenotype correlation analysis. Clinical Pharmacology and Therapeutics 68 (2000) 210-219
32. Garat A., et al. Characterisation of novel defective thiopurine S-methyltransferase allelic variants. Biochemical Pharmacology 76 (2008) 404-415
33. Hamdan-Khalil R., et al. In vitro characterization of four novel non-functional variants of the thiopurine S-methyltransferase. Biochemical and Biophysical Research Communications 309 (2003) 1005-1010
34. Hamdan-Khalil R., et al. Identification and functional analysis of two rare allelic variants of the thiopurine S-methyltransferase gene TPMT*16 and TPMT*19. Biochemical Pharmacology 69 (2005) 525-529
35. Kham S.K., Soh C.K., Aw D.C., Yeoh A.E., and TPMT*26. (208F → L), a novel mutation detected in a Chinese. British Journal of Clinical Pharmacology 68 (2009) 120-123
36. Krynetski E.Y., et al. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proceedings of the National Academy of Science of the United States of America 92 (1995) 949-953
37. Lindqvist M., et al. Identification of two novel sequence variants affecting thiopurine methyltransferase enzyme activity. Pharmacogenetics 14 (2004) 261-265
38. Lindqvist M., et al. Explaining TPMT genotype/phenotype discrepancy by haplotyping of TPMT*3A and identification of a novel sequence variant, TPMT*23. Pharmacogenet Genomics 17 (2007) 891-895
39. McLeod H.L., Miller D.R., and Evans W.E. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet 341 (1993) 1151
40. Sasaki T., Goto E., Konno Y., Hiratsuka M., and Mizugaki M. Three novel single nucleotide polymorphisms of the human thiopurine S-methyltransferase gene in Japanese individuals. Drug Metabolism and Pharmacokinetics 21 (2006) 332-336
41. Schaeffeler E., Eichelbaum M., Reinisch W., Zanger U.M., and Schwab M. Three novel thiopurine S-methyltransferase allelic variants (TPMT*20, *21, *22)-association with decreased enzyme function. Human Mutation 27 (2006) 976
42. Szumlanski C., et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA and Cell Biology 15 (1996) 17-30
43. Tai H.L., Krynetski E.Y., Schuetz E.G., Yanishevski Y., and Evans W.E. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proceedings of the National Academy of Science of the United States of America 94 (1997) 6444-6449
44. Ujiie S., Sasaki T., Mizugaki M., Ishikawa M., and Hiratsuka M. Functional characterization of 23 allelic variants of thiopurine S-methyltransferase gene (TPMT*2-*24). Pharmacogenet Genomics 18 (2008) 887-893
45. Hartford C., et al. Differential effects of targeted disruption of thiopurine methyltransferase on mercaptopurine and thioguanine pharmacodynamics. Cancer Research 67 (2007) 4965-4972
46. Dervieux T., et al. Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. Cancer Research 61 (2001) 5810-5816
47. Lennard L., Van Loon J.A., Lilleyman J.S., and Weinshilboum R.M. Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clinical Pharmacology and Therapeutics 41 (1987) 18-25
48. Lilleyman J.S., and Lennard L. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet 343 (1994) 1188-1190
49. Bostrom B., and Erdmann G. Cellular pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia. American Journal of Pediatric Hematology/Oncology 15 (1993) 80-86
50. Relling M.V., et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 354 (1999) 34-39
51. Schmiegelow K., et al. Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Leukemia 23 (2009) 557-564
52. Stanulla M., et al. Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Munster protocols. Blood 114 (2009) 1314-1318
53. Jackson R.C., Weber G., and Morris H.P. IMP dehydrogenase, an enzyme linked with proliferation and malignancy. Nature 256 (1975) 331-333
54. Price G.M., Hoffbrand A.V., Taheri M.R., and Evans J.P. Inosine monophosphate dehydrogenase activity in acute leukaemia. Leukemia Research 11 (1987) 525-528
55. Lucas D.L., Webster H.K., and Wright D.G. Purine metabolism in myeloid precursor cells during maturation. Studies with the HL-60 cell line. The Journal of Clinical Investigation 72 (1983) 1889-1900
56. Yamada Y., Goto H., Yoshino M., and Ogasawara N. IMP dehydrogenase and action of antimetabolites in human cultured blast cells. Biochimica et Biophysica Acta 1051 (1990) 209-214
57. Roberts R.L., Gearry R.B., Barclay M.L., and Kennedy M.A. IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance. The Pharmacogenomics Journal 7 (2007) 312-317
58. Yu J., Lemas V., Page T., Connor J.D., and Yu A.L. Induction of erythroid differentiation in K562 cells by inhibitors of inosine monophosphate dehydrogenase. Cancer Research 49 (1989) 5555-5560
59. Kerstens P.J., et al. Azathioprine-related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritis. Arthritis and Rheumatism 38 (1995) 142-145
60. Cummins D., Sekar M., Halil O., and Banner N. Myelosuppression associated with azathioprine-allopurinol interaction after heart and lung transplantation. Transplantation 61 (1996) 1661-1662
61. Marinaki A.M., et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 14 (2004) 181-187
62. Stocco G., et al. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clinical Pharmacology and Therapeutics 85 (2009) 164-172
63. Baldwin S.A., Mackey J.R., Cass C.E., and Young J.D. Nucleoside transporters: molecular biology and implications for therapeutic development. Molecular Medicine Today 5 (1999) 216-224
64. Baldwin S.A., et al. The equilibrative nucleoside transporter family, SLC29. Pflugers Archive 447 (2004) 735-743
65. Gray J.H., Owen R.P., and Giacomini K.M. The concentrative nucleoside transporter family SLC28. Pflugers Archive 447 (2004) 728-734
66. Zaza G., et al. Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. Blood 106 (2005) 1778-1785
67. Fotoohi A.K., Wrabel A., Moshfegh A., Peterson C., and Albertioni F. Molecular mechanisms underlying the enhanced sensitivity of thiopurine-resistant T-lymphoblastic cell lines to methyl mercaptopurineriboside. Biochemical Pharmacology 72 (2006) 816-823
68. Peng X.X., et al. Up-regulation of MRP4 and down-regulation of influx transporters in human leukemic cells with acquired resistance to 6-mercaptopurine. Leukemia Research 32 (2008) 799-809
69. Chen Z.S., Lee K., and Kruh G.D. Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. The Journal of Biological Chemistry 276 (2001) 33747-33754
70. Wijnholds J., et al. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proceedings of the National Academy of Science of the United States of America 97 (2000) 7476-7481
71. Wielinga P.R., et al. Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells. Molecular Pharmacology 62 (2002) 1321-1331
72. Ohtsuki S., Hori S., and Terasaki T. Molecular mechanisms of drug influx and efflux transport at the blood-brain barrier. Nippon Yakurigaku Zasshi 122 (2003) 55-64
73. Mori S., et al. Organic anion transporter 3 is involved in the brain-to-blood efflux transport of thiopurine nucleobase analogs. Journal of Neurochemistry 90 (2004) 931-941
74. Mendoza J.L., et al. MDR1 polymorphisms and response to azathioprine therapy in patients with Crohn's disease. Inflammatory Bowel Diseases 13 (2007) 585-590
75. Maybaum J., and Mandel H.G. Differential chromatid damage induced by 6-thioguanine in CHO cells. Experimental Cell Research 135 (1981) 465-468
76. Maybaum J., and Mandel H.G. Unilateral chromatid damage: a new basis for 6-thioguanine cytotoxicity. Cancer Research 43 (1983) 3852-3856
77. Maybaum J., Hink L.A., Roethel W.M., and Mandel H.G. Dissimilar actions of 6-mercaptopurine and 6-thioguanine in Chinese hamster ovary cells. Biochemical Pharmacology 34 (1985) 3677-3682
78. Karran P. Thiopurines, DNA damage, DNA repair and therapy-related cancer. British Medical Bulletin 79-80 (2006) 153-170
79. Krynetski E.Y., Krynetskaia N.F., Bianchi M.E., and Evans W.E. A nuclear protein complex containing high mobility group proteins B1 and B2, heat shock cognate protein 70, ERp60, and glyceraldehyde-3-phosphate dehydrogenase is involved in the cytotoxic response to DNA modified by incorporation of anticancer nucleoside analogues. Cancer Research 63 (2003) 100-106
80. Kawahata R.T., Holmberg C.A., Osburn B.I., Chuang L.F., and Chuang R.Y. Effect of 6-mercaptopurine ribonucleotides on DNA-dependent RNA polymerase activity. Molecular Pharmacology 18 (1980) 503-506
81. Lee M.Y., Byrnes J.J., Downey K.M., and So A.G. Mechanism of inhibition of deoxyribonucleic acid synthesis by 1-beta-D-arabinofuranosyladenosine triphosphate and its potentiation by 6-mercaptopurine ribonucleoside 5′-monophosphate. Biochemistry 19 (1980) 215-219
82. Tiede I., et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. Journal of Clinical Investigation 111 (2003) 1133-1145
83. Christie N.T., Drake S., Meyn R.E., and Nelson J.A. 6-Thioguanine-induced DNA damage as a determinant of cytotoxicity in cultured Chinese hamster ovary cells. Cancer Research 44 (1984) 3665-3671
84. Liliemark J., Pettersson B., Lafolie P., Zweig T., and Peterson C. Determination of plasma azathioprine and 6-mercaptopurine in patients with rheumatoid arthritis treated with oral azathioprine. Therapeutic Drug Monitoring 12 (1990) 339-343
85. Matsumura S., Hoshino T., Weizsaecker M., and Deen D.F. Paradoxical behavior of 6-mercaptopurine as a cytotoxic agent: decreasing cell kill with increasing drug dose. Cancer Treatment Reports 67 (1983) 475-480
86. Adamson P.C., Balis F.M., Hawkins M.E., Murphy R.F., and Poplack D.G. Desulfuration of 6-mercaptopurine. The basis for the paradoxical cytotoxicity of thiopurines in cultured human leukemic cells. Biochemical Pharmacology 46 (1993) 1627-1636
87. Brox L.W., Birkett L., and Belch A. Clinical pharmacology of oral thioguanine in acute myelogenous leukemia. Cancer Chemotherapy and Pharmacology 6 (1981) 35-38
88. Hayder S., Lafolie P., Bjork O., and Peterson C. 6-Mercaptopurine plasma levels in children with acute lymphoblastic leukemia: relation to relapse risk and myelotoxicity. Therapeutic Drug Monitoring 11 (1989) 617-622
89. Adamson P.C., et al. A phase II trial of continuous-infusion 6-mercaptopurine for childhood solid tumors. Cancer Chemotherapy and Pharmacology 26 (1990) 343-344
90. van der Werff Ten Bosch J., et al. Value of intravenous 6-mercaptopurine during continuation treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma: final results of a randomized phase III trial (58881) of the EORTC CLG. Leukemia 19 (2005) 721-726
91. McLeod H.L., Relling M.V., Liu Q., Pui C.H., and Evans W.E. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood 85 (1995) 1897-1902
92. Lennard L., Lilleyman J.S., Van Loon J., and Weinshilboum R.M. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336 (1990) 225-229
93. Eichelbaum M., Ingelman-Sundberg M., and Evans W.E. Pharmacogenomics and individualized drug therapy. Annual Review of Medicine 57 (2006) 119-137
94. Zhang L.R., et al. Efficient screening method of the thiopurine methyltransferase polymorphisms for patients considering taking thiopurine drugs in a Chinese Han population in Henan Province (central China). Clinica Chimica Acta; International Journal of Clinical Chemistry 376 (2007) 45-51
95. Fakhoury M., et al. Should TPMT genotype and activity be used to monitor 6-mercaptopurine treatment in children with acute lymphoblastic leukaemia?. Journal of Clinical Pharmacy and Therapeutics 32 (2007) 633-639
96. Lennard L. TPMT in the treatment of Crohn's disease with azathioprine. Gut 51 (2002) 143-146
97. Sandborn W., et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database of Systematic Reviews (Online) (2000) CD000545
98. Schwab M., et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 12 (2002) 429-436
99. Rocha J.C., et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 105 (2005) 4752-4758
100. Stet E.H., et al. Decrease in S-adenosylmethionine synthesis by 6-mercaptopurine and methylmercaptopurine ribonucleoside in Molt F4 human malignant lymphoblasts. Biochemistry Journal 304 Pt 1 (1994) 163-168